Study Assesses Epidemiology of Carbapenem-resistant Enterobacteriaceae
the ONA take:
Most carbapenem-resistant enterobacteriacecae (CRE) cases in the United States are associated with a high prevalence of prior hospitalizations or indwelling devices and discharge to long-term care settings, a study published in JAMA has shown.
Because CRE cases have been increasingly reported worldwide as a cause of infection with high-mortality rates, researchers sought to determine the population-based CRE incidence in seven US geographical areas.
For the study, researchers analyzed case records from persons living in 1 of 7 US metropolitan areas in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, and Oregon.
Results showed that the incidence of CRE was 2.93 per 100,000 people. Researchers also found that the majority of CRE cases were in women.
CRE cases were significantly higher than predicted for Georgia, Maryland, and New York, while Colorado, New Mexico, and Oregon had significantly fewer cases than predicted.
The study demonstrated that most CRE cases occurred in patients with prior hospitalizations or indwelling devices, and the majority of admitted cases results in discharge to a long-term care setting.
The carbapenem antibiotic class includes imipenem, meropenem, doripenem, and ertapenem. Extended-spectrum cephalosporin-resistant enterobacteriaceae are typically susceptible to carbapenems except ertapenem.
Most carbapenem-resistant enterobacteriacecae (CRE) cases associated with a high prevalence of prior hospitalizations.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|